FDA Approves Merck's Vaccine For Adult Invasive Pneumococcal Disease
By Emon Reiser
The Food and Drug Administration approved Merck's Capvaxive, a vaccine to prevent the invasive bacterial infection pneumococcal disease in adults age 50 or older.
Merck said that across four Phase 3 studies, Capvaxive "demonstrated robust immune responses in both vaccine-naïve and vaccine-experienced adult populations." Complications from invasive pneumococcal disease can lead to hospitalization, organ damage and death.
The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices is expected to meet later this month to discuss and make recommendations for the vaccine.
Merck's other pneumococcal vaccine, Vaxneuvance, provided $219 million in sales in Merck's first quarter.
Write to Emon Reiser at emon.reiser@wsj.com
-0-
Write to Emon Reiser at emon.reiser@wsj.com
(END) Dow Jones Newswires
June 17, 2024 18:05 ET (22:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations